Krystal Biotech, Inc. KRYS 深 沪
已收盘 02-06 16:00:00 美东时间
272.74
+5.100
+1.91%
华盛通- 最 高277.11
- 今 开276.89
- 成交量 32.76万股
- 最 低 260.03
- 昨 收 267.64
- 总市值 79.09亿
- 52周最高 295.98
- 市盈率 静 90.97
- 换手率 1.13%
- 52周最低 122.80
- 委 比 -79.78%
- 总股本 2899.75万
- 历史最高 295.98
- 量 比 1.19
- 振 幅 6.38%
- 历史最低 8.03
- 每 手 1
- 风险率 42.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
Goldman Sachs Maintains Buy on Krystal Biotech, Raises Price Target to $327
Goldman Sachs analyst Andrea Tan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $206 to $327.
02-03 01:51
美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $318
B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $288 to $318.
01-23 02:07
美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Krystal Biotech To Report Interim Clinical Study Update From CORAL-1 Phase 1 Trial Of KB407 In Participants With Cystic Fibrosis
Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) today announced that it will host an investor conference call and webcast tomorrow, Thursday, January 8, 2026, at 4:30 pm ET, to disclose an interim clinical update
01-08 05:07
Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis
Krystal Biotech will host an investor call on January 8, 2026, at 4:30 pm ET to discuss interim results from its Phase 1 CORAL-1 study of KB407 for cystic fibrosis, focusing on the highest dose cohort and molecular assessments of CFTR protein expression. The live webcast will be available at [link], with an archived version on the company’s website for 30 days. Krystal Biotech is a global biotech company developing genetic medicines for high unme...
01-07 21:05
Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference
Krystal Biotech, Inc. (NASDAQ: KRYS) announces its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco. Krish S. Krishnan, the Company's Chairman and CEO, will present at 10:30 am ET / 7:30 am PT and host investor meetings. The presentation will be webcast live and available on the Company's website. Krystal Biotech is a global biotech company focused on developing genetic medicines for disease...
01-05 13:00
Krystal Biotech announces resignation of longtime board member
Krystal Biotech ( ($KRYS) ) has issued an update. On December 22, 2025, Krystal...
2025-12-24 06:20
